Elan sees profits turnaround in Q1

Irish pharmaceutical company Elan's made a first-quarter operating profit of €24.5m reversing losses of €40m in the same period last year.

The company's benefitting from growth in sales for its multiple sclerosis treatment Tysabri and is on track to report its first annual profit in over five years.